Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9BRS2

UPID:
RIOK1_HUMAN

ALTERNATIVE NAMES:
RIO kinase 1

ALTERNATIVE UPACC:
Q9BRS2; B2RB28; Q8NDC8; Q96NV9

BACKGROUND:
The Serine/threonine-protein kinase RIO1, known alternatively as RIO kinase 1, is integral to ribosomal biogenesis, specifically in the maturation of the 40S ribosomal subunit. It facilitates the transition of 18S-E pre-rRNA into mature 18S rRNA and ensures the efficient recycling of NOB1 and PNO1. The protein's kinase domain, primarily acting as an ATPase, is crucial for its association with the 40S subunit. RIO1 also serves as an adapter, enhancing the PRMT5 complex's methylation process by recruiting NCL/nucleolin.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Serine/threonine-protein kinase RIO1 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.